Richard D. Truesdell, Jr.

Davis Polk advised Royalty Pharma plc and the selling shareholders on Royalty Pharma’s $728 million secondary offering of 17,343,037 of its Class A ordinary shares by certain selling…

Davis Polk is advising Morgan Stanley & Co. LLC as lead financial adviser and sole placement agent to RMG Acquisition Corp. (“RMG”), a special purpose acquisition company, in connection…

  Davis Polk advised the representatives of the several underwriters in connection with the $96 million initial public offering by Mission Produce, Inc. of 8,000,000 shares of its…

Davis Polk advised Gilead Sciences, Inc. in connection with an SEC-registered offering of $7.25 billion aggregate principal amount of senior notes, consisting of (i) $500 million aggregate…

Davis Polk advised MDLIVE Inc. in connection with its private placement of approximately $50 million in shares of its Series F preferred stock.MDLIVE offers virtual healthcare services to…

Davis Polk advised the joint book-running managers on an SEC-registered offering by Valero Energy Corporation of $2.5 billion aggregate principal amount of its floating-rate senior notes…

Davis Polk advised the book-running manager in connection with the $156.7 million SEC-registered follow-on offering of 2,207,380 shares of Class A common stock of Hamilton Lane Incorporated…

Davis Polk advised Royalty Pharma plc in connection with its Rule 144A/Regulation S offering of $1 billion aggregate principal amount of its 0.75% senior notes due 2023, $1 billion…

Davis Polk advised the lead book-running manager and representative of the underwriters in connection with an underwritten secondary offering of 6,000,000 shares of common stock of Cal…

Davis Polk advised CureVac N.V. on its $245.3 million initial public offering of 15,333,332 of its common shares, which includes 1,999,999 common shares from the full exercise of the…